ArticleBlood2018
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.Blood advances · 2020Pooled it
- Trial
- Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.Blood advances · 2022Trial
- Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.Blood advances · 2022Trial
- Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.The Journal of clinical investigation · 2022Trial
- Trial
- Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.British journal of haematology · 2019Trial
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.Leukemia · 2026Article
- Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.International journal of molecular sciences · 2026Review
- Proteogenomic features define subtypes of mantle cell lymphoma.Blood advances · 2026Article
- Leukemic Non-Nodal Mantle Cell Lymphoma Presenting with Traumatic Splenic Rupture.Hematology reports · 2026Article
- The expression of MALAT1 long non-coding RNA is associated with good prognosis in mantle cell lymphoma.Scientific reports · 2026Article
- Enhancing breast cancer diagnosis: non-invasive prediction of MKI-67 (Ki67) expression using ultrasound images.BMC cancer · 2025Article
- Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target.Hematological oncology · 2025Review
- Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma.Genes · 2025Article
- [Indolent leukemic non-nodal mantle cell lymphoma with TP53 mutation misdiagnosed as chronic lymphocytic leukemia: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.Blood cancer journal · 2024Article
- Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.Blood advances · 2024Review
- Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China.Annals of hematology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
27 authors at 11 institutions in 4 countries.
Funding
Abstract
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy, but some patients have a very indolent evolution. This heterogeneous course is related, in part, to the different biological characteristics of conventional MCL (cMCL) and the distinct subgroup of leukemic nonnodal MCL (nnMCL). Robust criteria to distinguish these MCL subtypes and additional biological parameters that influence their evolution are not well defined. We describe a novel molecular assay that reliably distinguishes cMCL and nnMCL using blood samples. We trained a 16-gene assay (L-MCL16 assay) on the NanoString platform using 19 purified leukemic samples. The locked assay was applied to an independent cohort of 70 MCL patients with leukemic presentation. The assay assigned 37% of cases to nnMCL and 56% to cMCL. nnMCL and cMCL differed in nodal presentation, lactate dehydrogenase, immunoglobulin heavy chain gene mutational status, management options, genomic complexity, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.